These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

460 related articles for article (PubMed ID: 32489646)

  • 1. Targeting the "PVR-TIGIT axis" with immune checkpoint therapies.
    Gorvel L; Olive D
    F1000Res; 2020; 9():. PubMed ID: 32489646
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TIGIT and CD96: new checkpoint receptor targets for cancer immunotherapy.
    Dougall WC; Kurtulus S; Smyth MJ; Anderson AC
    Immunol Rev; 2017 Mar; 276(1):112-120. PubMed ID: 28258695
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNAM-1 and the TIGIT/PVRIG/TACTILE Axis: Novel Immune Checkpoints for Natural Killer Cell-Based Cancer Immunotherapy.
    Sanchez-Correa B; Valhondo I; Hassouneh F; Lopez-Sejas N; Pera A; Bergua JM; Arcos MJ; Bañas H; Casas-Avilés I; Durán E; Alonso C; Solana R; Tarazona R
    Cancers (Basel); 2019 Jun; 11(6):. PubMed ID: 31234588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hitting the complexity of the TIGIT-CD96-CD112R-CD226 axis for next-generation cancer immunotherapy.
    Jin HS; Park Y
    BMB Rep; 2021 Jan; 54(1):2-11. PubMed ID: 33298247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repositioning liothyronine for cancer immunotherapy by blocking the interaction of immune checkpoint TIGIT/PVR.
    Zhou X; Du J; Wang H; Chen C; Jiao L; Cheng X; Zhou X; Chen S; Gou S; Zhao W; Zhai W; Chen J; Gao Y
    Cell Commun Signal; 2020 Sep; 18(1):142. PubMed ID: 32894141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PVRIG and PVRL2 Are Induced in Cancer and Inhibit CD8
    Whelan S; Ophir E; Kotturi MF; Levy O; Ganguly S; Leung L; Vaknin I; Kumar S; Dassa L; Hansen K; Bernados D; Murter B; Soni A; Taube JM; Fader AN; Wang TL; Shih IM; White M; Pardoll DM; Liang SC
    Cancer Immunol Res; 2019 Feb; 7(2):257-268. PubMed ID: 30659054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TIGIT blockade enhances functionality of peritoneal NK cells with altered expression of DNAM-1/TIGIT/CD96 checkpoint molecules in ovarian cancer.
    Maas RJ; Hoogstad-van Evert JS; Van der Meer JM; Mekers V; Rezaeifard S; Korman AJ; de Jonge PK; Cany J; Woestenenk R; Schaap NP; Massuger LF; Jansen JH; Hobo W; Dolstra H
    Oncoimmunology; 2020 Nov; 9(1):1843247. PubMed ID: 33224630
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Pathways: Targeting CD96 and TIGIT for Cancer Immunotherapy.
    Blake SJ; Dougall WC; Miles JJ; Teng MW; Smyth MJ
    Clin Cancer Res; 2016 Nov; 22(21):5183-5188. PubMed ID: 27620276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatocellular Carcinoma Cells Up-regulate PVRL1, Stabilizing PVR and Inhibiting the Cytotoxic T-Cell Response via TIGIT to Mediate Tumor Resistance to PD1 Inhibitors in Mice.
    Chiu DK; Yuen VW; Cheu JW; Wei LL; Ting V; Fehlings M; Sumatoh H; Nardin A; Newell EW; Ng IO; Yau TC; Wong CM; Wong CC
    Gastroenterology; 2020 Aug; 159(2):609-623. PubMed ID: 32275969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in therapeutic targeting of immune checkpoints receptors within the CD96-TIGIT axis: clinical implications and future perspectives.
    Farhangnia P; Akbarpour M; Yazdanifar M; Aref AR; Delbandi AA; Rezaei N
    Expert Rev Clin Immunol; 2022 Dec; 18(12):1217-1237. PubMed ID: 36154551
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DNAM-1 versus TIGIT: competitive roles in tumor immunity and inflammatory responses.
    Shibuya A; Shibuya K
    Int Immunol; 2021 Nov; 33(12):687-692. PubMed ID: 34694361
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction of PVR/PVRL2 with TIGIT/DNAM-1 as a novel immune checkpoint axis and therapeutic target in cancer.
    Stamm H; Wellbrock J; Fiedler W
    Mamm Genome; 2018 Dec; 29(11-12):694-702. PubMed ID: 30132062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TIGIT: a novel immunotherapy target moving from bench to bedside.
    Solomon BL; Garrido-Laguna I
    Cancer Immunol Immunother; 2018 Nov; 67(11):1659-1667. PubMed ID: 30232519
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy.
    Chiang EY; Mellman I
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35379739
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Poliovirus receptor (PVR)-like protein cosignaling network: new opportunities for cancer immunotherapy.
    Wu B; Zhong C; Lang Q; Liang Z; Zhang Y; Zhao X; Yu Y; Zhang H; Xu F; Tian Y
    J Exp Clin Cancer Res; 2021 Aug; 40(1):267. PubMed ID: 34433460
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
    Boissière-Michot F; Chateau MC; Thézenas S; Guiu S; Bobrie A; Jacot W
    Front Immunol; 2022; 13():1058424. PubMed ID: 36544779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The N-linked glycosylations of TIGIT Asn
    Lin YX; Hung MC; Hsu JL; Hsu JM
    Biochem Biophys Res Commun; 2021 Jul; 562():9-14. PubMed ID: 34030043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrinsic Expression of Immune Checkpoint Molecule TIGIT Could Help Tumor Growth
    Zhou XM; Li WQ; Wu YH; Han L; Cao XG; Yang XM; Wang HF; Zhao WS; Zhai WJ; Qi YM; Gao YF
    Front Immunol; 2018; 9():2821. PubMed ID: 30555485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Nectin family ligands, PVRL2 and PVR, in cancer immunology and immunotherapy.
    Murakami K; Ganguly S
    Front Immunol; 2024; 15():1441730. PubMed ID: 39156900
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancing T cell anti-tumor efficacy with a PD1-TIGIT chimeric immune-checkpoint switch receptor.
    Zhao J; Dong J; Deng C; Zhang Q; Sun S; Li H; Bai Y; Deng H
    Oncoimmunology; 2023; 12(1):2265703. PubMed ID: 37808405
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.